API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
0
Other Certificates
Other Suppliers
0
USA (Orange Book)
0
Europe
Canada
0
Australia
0
South Africa
Uploaded Dossiers
U.S. Medicaid
0
Annual Reports
0
0
Details:
According to IQVIA, the portfolio has annual sales of approximately $26 million dollars and includes drugs such as: ATARAX®, NOOTROPIL®, XUZAL®, and VIRLIX®.
Lead Product(s): Piracetam
Therapeutic Area: Neurology Product Name: Nootropil
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: UCB Pharma S.A
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership June 22, 2021